PCM
FULC icon

Penserra Capital Management’s Fulcrum Therapeutics FULC Stock Holding History

Penserra Capital Management’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-925
Closed -$26K – 1426
2021
Q3 		$26K Buy
925
+180
+24% +$3.41K ﹤0.01% 1207
2021
Q2 		$7K Buy
745
+20
+3% +$202 ﹤0.01% 1294
2021
Q1 		$8K Buy
725
+95
+15% +$1.18K ﹤0.01% 1057
2020
Q4 		$7K Buy
+630
New +$7.12K ﹤0.01% 958

Other funds holding FULC

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Penserra Capital Management's FULC Position: Q4 2021 in Review

Penserra Capital Management sold out of Fulcrum Therapeutics (FULC) in Q4 2021, closing a stake of 925 shares — an estimated $26K sold.

Penserra Capital Management first reported a position in FULC in Q4 2020 and held it in 4 quarters. The position peaked at $26K in Q3 2021. 110 funds tracked by Wall St. Rank hold FULC as of Q4 2021.

  • Penserra Capital Management reported no remaining Fulcrum Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Penserra Capital Management sold 925 Fulcrum Therapeutics shares in Q4 2021, an estimated $26K.
  • Penserra Capital Management first reported a position in Fulcrum Therapeutics in Q4 2020 and held it in 4 quarters.
  • Penserra Capital Management's Fulcrum Therapeutics position peaked at $26K in Q3 2021.
  • 110 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q4 2021.

Based on Penserra Capital Management's 13F filing for Q4 2021, filed 15 Feb 2022.